Patient Information

CSL Behring is committed to improving the quality of life for patients with rare diseases, including immune deficiency disorders, haemophilia and von Willebrand disease. Our therapies are also used for congenital fibrinogen deficiency, congenital factor XIII deficiency, rapid warfarin reversal and to prevent haemolytic disease of the newborn.


CSL Behring provides a range of therapies to treat coagulation disorders such as haemophilia, von Willebrand disease, congenital fibrinogen deficiency and congenital factor XIII deficiency.

CSL Behring also manufactures a product for rapid warfarin reversal. Warfarin is a medicine which thins the blood and is used to reduce the risk of blood clots. When a person on warfarin experiences a serious bleeding episode, it may be necessary to reverse the effects of warfarin to stop the bleeding.

Haemophilia is a problem with the blood in which there is not enough of one of the clotting factors needed for blood clots to form.

People with von Willebrand disease also have a problem with one of the clotting factors in the blood; this particular clotting factor is known as von Willebrand factor.

Congenital fibrinogen deficiency is where an essential protein required for a blood clot to form is either missing, significantly reduced or dysfunctional.

Congenital factor XIII deficiency is where a protein required for stabilization of the blood clot is significantly reduced.


In the area of immunology, CSL Behring provides a range of therapies for immune deficiency disorders, hereditary angioedema and to prevent haemolytic disease of the newborn.

Hereditary angioedema is a rare genetic condition that can cause considerable swelling in various body tissues.

Immune deficiency disorders - in general, immunodeficiency means that one or more components of the immune system are either absent or are not working properly.

Haemolytic disease of the newborn is caused when the blood group of the mother and baby are not compatible.